U.S. Markets open in 7 hrs 24 mins

New Research: Key Drivers of Growth for American Tower Corporation (REIT), Lowe's Companies, Mimecast, Live Nation Entertainment, Intercept Pharmaceuticals, and Coherus BioSciences — Factors of Influence, Major Initiatives and Sustained Production

NEW YORK, March 05, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of American Tower Corporation (REIT) (AMT), Lowe's Companies, Inc. (LOW), Mimecast Limited (MIME), Live Nation Entertainment, Inc. (LYV), Intercept Pharmaceuticals, Inc. (ICPT), and Coherus BioSciences, Inc. (CHRS), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

AMT DOWNLOAD: http://Capital-Review.com/register/?so=AMT
LOW DOWNLOAD: http://Capital-Review.com/register/?so=LOW
MIME DOWNLOAD: http://Capital-Review.com/register/?so=MIME
LYV DOWNLOAD: http://Capital-Review.com/register/?so=LYV
ICPT DOWNLOAD: http://Capital-Review.com/register/?so=ICPT
CHRS DOWNLOAD: http://Capital-Review.com/register/?so=CHRS

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine American Tower Corporation (REIT) (AMT), Lowe's Companies, Inc. (LOW), Mimecast Limited (MIME), Live Nation Entertainment, Inc. (LYV), Intercept Pharmaceuticals, Inc. (ICPT), and Coherus BioSciences, Inc. (CHRS) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 1st, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

AMERICAN TOWER CORPORATION (REIT) (AMT) REPORT OVERVIEW

American Tower Corporation (REIT)'s Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, American Tower Corporation (REIT) reported revenue of $1,785.50MM vs $1,680.70MM (up 6.24%) and analysts estimated basic earnings per share $0.83 vs $0.70 (up 18.57%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, American Tower Corporation (REIT) reported revenue of $6,663.90MM vs $5,785.70MM (up 15.18%) and analysts estimated basic earnings per share $2.69 vs $2.00 (up 34.50%). Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.73. The estimated EPS forecast for the next fiscal year is $8.42 and is expected to report on February 26th, 2020.

To read the full American Tower Corporation (REIT) (AMT) report, download it here: http://Capital-Review.com/register/?so=AMT

-----------------------------------------

LOWE'S COMPANIES, INC. (LOW) REPORT OVERVIEW

Lowe's Companies' Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, Lowe's Companies reported revenue of $17,415.00MM vs $16,770.00MM (up 3.85%) and analysts estimated basic earnings per share $0.78 vs $1.05 (down 25.71%). For the twelve months ended January 31st, 2018 vs January 31st, 2017, Lowe's Companies reported revenue of $68,619.00MM vs $65,017.00MM (up 5.54%) and analysts estimated basic earnings per share $4.09 vs $3.48 (up 17.53%). Analysts expect earnings to be released on May 22nd, 2019. The report will be for the fiscal period ending April 30th, 2019. Reported EPS for the same quarter last year was $1.19. The estimated EPS forecast for the next fiscal year is $6.94 and is expected to report on February 26th, 2020.

To read the full Lowe's Companies, Inc. (LOW) report, download it here: http://Capital-Review.com/register/?so=LOW

-----------------------------------------

MIMECAST LIMITED (MIME) REPORT OVERVIEW

Mimecast's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Mimecast reported revenue of $87.61MM vs $67.27MM (up 30.23%) and analysts estimated basic earnings per share $0.01 vs -$0.05. For the twelve months ended March 31st, 2018 vs March 31st, 2017, Mimecast reported revenue of $261.90MM vs $186.56MM (up 40.38%) and analysts estimated basic earnings per share -$0.22 vs -$0.10. Analysts expect earnings to be released on May 13th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.09. The estimated EPS forecast for the next fiscal year is $0.10 and is expected to report on May 13th, 2019.

To read the full Mimecast Limited (MIME) report, download it here: http://Capital-Review.com/register/?so=MIME

-----------------------------------------

LIVE NATION ENTERTAINMENT, INC. (LYV) REPORT OVERVIEW

Live Nation Entertainment's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Live Nation Entertainment reported revenue of $3,835.25MM vs $3,440.31MM (up 11.48%) and basic earnings per share $0.73 vs $0.56 (up 30.36%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Live Nation Entertainment reported revenue of $10,337.45MM vs $8,354.93MM (up 23.73%) and analysts estimated basic earnings per share -$0.48 vs -$0.23. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.24. The estimated EPS forecast for the next fiscal year is $0.68 and is expected to report on February 27th, 2020.

To read the full Live Nation Entertainment, Inc. (LYV) report, download it here: http://Capital-Review.com/register/?so=LYV

-----------------------------------------

INTERCEPT PHARMACEUTICALS, INC. (ICPT) REPORT OVERVIEW

Intercept Pharmaceuticals' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Intercept Pharmaceuticals reported revenue of $46.99MM vs $41.33MM (up 13.67%) and analysts estimated basic earnings per share -$2.18 vs -$2.89. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Intercept Pharmaceuticals reported revenue of $130.96MM vs $24.95MM (up 424.85%) and analysts estimated basic earnings per share -$14.38 vs -$16.74. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$3.22. The estimated EPS forecast for the next fiscal year is -$5.51 and is expected to report on February 27th, 2020.

To read the full Intercept Pharmaceuticals, Inc. (ICPT) report, download it here: http://Capital-Review.com/register/?so=ICPT

-----------------------------------------

COHERUS BIOSCIENCES, INC. (CHRS) REPORT OVERVIEW

Coherus BioSciences' Recent Financial Performance

For the twelve months ended December 31st, 2017 vs December 31st, 2016, Coherus BioSciences reported revenue of $1.56MM vs $190.11MM (down 99.18%) and analysts estimated basic earnings per share -$4.48 vs -$3.04. Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.74. The estimated EPS forecast for the next fiscal year is -$0.30 and is expected to report on February 27th, 2020.

To read the full Coherus BioSciences, Inc. (CHRS) report, download it here: http://Capital-Review.com/register/?so=CHRS

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Nicole Garrens, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.